News

ONCOLife presents an exclusive interview with Dr. Miguel-Angel Perales, Co-Chair of the CAR T Vision initiative, as he shares ...
ONCOLife presents an exclusive interview with Lorna Warwick, CEO of Lymphoma Coalition. In this session, we explore the critical role of patient advocacy in improving access to CAR T-cell therapy — a ...
Vividion Therapeutics and Bayer are advancing VVD-214, the world’s only clinical-stage covalent WRN inhibitor, for MSI-high cancers including colorectal, endometrial, ovarian, and gastric tumors.
ONCOLife presents an exclusive interview with Nick Slack, Chairman and CEO of The START Center for Cancer Research. In this session, we explore how the integration of the Carolina Urologic Research ...
The Innovation-Implementation Divide What the Index underscores is not a failure of scientific progress, but rather the growing complexity of applying that progress in real-world clinical care. Three ...
In the Phase 3 KEYNOTE-689 trial, pembrolizumab (Keytruda) combined with standard care significantly improved event-free survival (EFS) in patients with resectable, locally advanced head and neck ...
We are pleased to present an exclusive interview with Dana Brown, CEO and Chairman of the Board at iCAD Inc., to explore the future of breast cancer screening and the role of artificial intelligence ...
ADCs are at the forefront of cancer treatment, providing targeted therapies with promising results for lung cancer. We have an exclusive interview with Dr. Maria de Miguel, to discuss the latest ...
Oncolytic viruses are emerging as a promising development in cancer treatment. We had an interview with Dr. Thomas C. Heineman, CMO at Oncolytics Biotech, where we discuss the groundbreaking potential ...
With FDA Fast Track designation, the new non-opioid pain medication SRP-001 shows promising Phase 1 trial results, offering a safer alternative for pain management.
Rznomics has received FDA Orphan Drug Designation for RZ-001, a novel RNA-based RZ-001 therapy for Liver Cancer and Hepatocellular carcinoma.